Mode
Text Size
Log in / Sign up

TTI-0102 Improves Fatigue Scores in MELAS Syndrome Patients During Randomized Phase 2 TrialNew Drug Reduces Fatigue in Rare Mitochondrial Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret TTI-0102 fatigue results cautiously given the small Phase 2 sample size of 9 patients with MELAS syndrome.

This randomized, single-blind, placebo-controlled Phase 2 trial evaluated TTI-0102 in 9 patients with MELAS syndrome caused by mtDNA m.3243A>G mutation. Participants had moderate disease severity defined by NMDAS score 15-45 and heteroplasmy greater than 50%. The study setting was multi-center with a minimum 12-week treatment duration. The trial enrolled patients across multiple sites.

Patients received TTI-0102 at 2.75 g/day for one week then 5.5 g/day or weight-based dosing at 60 +/- 5 mg/kg TTI-0102 versus placebo. Primary outcome analysis showed significant improvement in Modified Fatigue Impact Scale total scores in TTI-0102-treated patients at 60 mg/kg/day average dose compared to placebo (p=0.04). Secondary outcomes included pharmacokinetic parameters, safety, and pharmacodynamic biomarkers.

Biomarker analysis revealed increased plasma pyruvate (p=0.03) and decreased tryptophan (p<0.01). Pantothenic acid and taurine levels were elevated, while lactate showed no change. GDF-15, FGF-21, and 12-minute walk distance demonstrated no treatment-related changes.

Safety data noted gastrointestinal side effects including nausea, vomiting, and diarrhea. Dropout occurred in patients 50 kg receiving fixed 5.5 g/day dosing, though the drug was safe and well-tolerated in MELAS patients while treated with less than 65 mg/kg/day. Limitations included GSH/GSSG measurements confounded by sample stability issues. Evidence supports advancing TTI-0102 to larger Phase 2b/3 trials in mitochondrial disease employing weight-based dosing.

New Drug Reduces Fatigue in Rare Mitochondrial Disease

Mitochondrial diseases are a group of rare conditions that affect how your body makes energy. They often run in families or happen by chance. While they are rare, they can be very hard to live with.

The main problem today is a tough choice. Patients often have to pick between feeling sick or feeling tired. The current standard treatment can help lower dangerous levels of a substance in the blood, but it causes terrible side effects. Many patients get severe nausea, vomiting, and diarrhea.

This is frustrating because the medicine works to save their health, but their bodies reject it. Some patients stop taking the medicine because they cannot handle the pain. This leaves them with high levels of the bad substance and no energy.

The Surprising Shift

Scientists have been trying to fix this problem for years. They needed a way to get the medicine into the body without causing a stomach upset. The new drug, called TTI-0102, is a special version of the old medicine.

Think of the old medicine like a firecracker. It explodes all at once, giving a huge dose that hurts your stomach. The new drug is like a slow-burning candle. It releases the medicine gently over a full day. This keeps the levels steady and avoids the painful spikes that hurt the gut.

What Scientists Didn't Expect

When researchers tested this new drug, they saw something exciting. The patients who took it reported feeling less tired. They could walk further and feel more like themselves.

But there was a catch. The drug only worked well at a specific dose. If the dose was too high, the stomach still got upset. If it was too low, it did not help enough. Finding the perfect middle ground was the key to making this work.

To understand this, think of your cells as a factory. They need specific parts to run machines. One part is missing or broken in these diseases.

The new drug delivers three helpful things at once. It brings in the missing part, adds antioxidants to fight damage, and gives extra fuel for the energy machines. Because it releases slowly, it acts like a steady stream of fuel rather than a sudden dump.

This steady stream keeps the factory running smoothly. It stops the dangerous buildup of waste products that usually makes patients feel worse. It is like clearing a traffic jam on a busy highway so cars can move freely again.

The team tested this drug on nine patients with a specific type of mitochondrial disease called MELAS. These patients had a known genetic mutation that caused their cells to fail.

They gave some patients a fake pill and others the real drug. The real drug started at a low dose and increased over a week. The team watched closely to see how the patients felt and how their bodies reacted. They measured energy levels, fatigue, and how well the drug stayed in the blood.

The results were clear. Patients taking the drug felt significantly less tired than those on the fake pill. The improvement happened over time, starting around four weeks and getting better until about three months.

The drug also changed the chemistry in the blood in a good way. It raised levels of important nutrients that help energy production. It did this without raising the dangerous waste products that usually build up in these patients.

But there's a catch. The drug did not work for everyone equally. Patients who weighed less had trouble tolerating the standard dose. They had to take less medicine to avoid stomach pain. This means doctors must adjust the dose based on each person's weight.

Doctors see how hard it is for patients to stick with current treatments. When a patient vomits after every dose, they eventually stop taking the medicine. This study shows a path forward.

By using a weight-based dose, doctors can keep the medicine safe for more people. This approach could change how we treat many mitochondrial diseases. It opens the door for testing this drug on other conditions that affect energy production.

If you or a loved one has a mitochondrial disease, this is hopeful news. It means there might be a treatment that actually works without making you feel sick.

However, this drug is not on store shelves yet. It is still in the research phase. You cannot buy it at a pharmacy right now. The next step is to test it on more people to prove it is safe and effective for everyone.

This study was small, with only nine patients. Also, the drug did not help every symptom. It did not fix all the problems caused by the disease, just the fatigue and energy levels.

The researchers also noted some issues with measuring certain chemicals in the blood. These measurements were hard to read because the samples were not stable. This means scientists need to keep studying to get a full picture of how the drug works.

Scientists plan to test this drug on more people soon. They will also study it for other rare diseases that affect energy production. The goal is to get it approved for use by doctors everywhere.

This process takes time. Researchers must prove the drug is safe for large groups of people before it becomes a standard treatment. But the path is clear. With careful testing, this new medicine could bring real relief to many families struggling with fatigue and pain.

Study Details

Study typeRct
Sample sizen = 3
EvidenceLevel 2
PublishedMar 2026
View Original Abstract ↓
BackgroundCysteamine is the only disease-modifying therapy for nephropathic cystinosis and has shown promise in mitochondrial disorders, but its clinical utility is limited by poor tolerability due to high peak concentrations with existing formulations. TTI-0102 is a novel natural controlled-release cysteamine prodrug designed to provide sustained cysteamine exposure with improved tolerability. MethodsA multi-center, randomized, single-blind, placebo-controlled Phase 2 trial enrolled 9 patients with MELAS syndrome caused by mtDNA m.3243A>G mutation (>50% heteroplasmy) and moderate disease severity (NMDAS score 15-45). Patients received placebo (n=3) or TTI-0102 at 2.75 g/day for one week then 5.5 g/day (n=6, equivalent to 2.5 g/day cysteamine base). Pharmacokinetic parameters, safety, and pharmacodynamic biomarkers including pyruvate, taurine, pantothenic acid, tryptophan, GSH/GSSG, lactate, GDF-15, and FGF-21 were assessed. Clinical efficacy was evaluated using the Modified Fatigue Impact Scale (MFIS) and 12-minute walk test. ResultsTTI-0102 demonstrated expected gastrointestinal side effects (nausea, vomiting, diarrhea) consistent with the cysteamine class, with dropout occurring in patients 50 kg receiving fixed 5.5 g/day dosing. Weight-based dosing at 60 {+/-} 5 mg/kg TTI-0102 (~26 mg/kg cysteamine base equivalent) achieved sustained 24-hour cysteamine exposure with half the daily dose and peak concentrations lower than expected by dose proportionality, compared to approved formulations (Procysbi(R): 56 mg/kg, peak 2.5 mg/L vs. TTI-0102: 26 mg/kg, peak ~2 mg/L). TTI-0102 significantly elevated pantothenic acid (plateauing at 2 weeks) and taurine levels, providing mitochondrial cofactor support and antioxidant effects. Statistically significant pharmacodynamic effects included increased plasma pyruvate (p=0.03) without lactate elevation, suggesting enhanced glycolytic flux, and decreased tryptophan (p<0.01), potentially reducing oxidative stress from neurotoxic kynurenine pathway metabolites. Interestingly, increase in plasma pyruvate and decrease in tryptophan were negligible at doses up to 40 mg/kg/day, optimal at 60 mg/kg/day, and slightly less at 65 mg/kg/day. GSH/GSSG measurements were confounded by sample stability issues. GDF-15, FGF-21, and 12-minute walk distance showed no treatment-related changes. Most notably, MFIS total scores demonstrated significant improvement in TTI-0102-treated patients at 60 mg/kg/day average dose compared to placebo (p=0.04). Polynomial regression revealed therapeutic onset at ~4 weeks, maximal benefit at ~12 weeks, and subsequent plateau. ConclusionsThis Phase 2 trial provides proof-of-concept that TTI-0102 is safe and well-tolerated in MELAS patients while treated with less than 65 mg/kg/day, with efficacy signals in fatigue reduction, a cardinal symptom affecting 71-100% of mitochondrial disease patients. The drugs tri-faceted mechanism through sustained cysteamine, taurine, and pantothenic acid delivery addresses oxidative stress, mitochondrial energy metabolism, and cofactor deficiency. Significant MFIS improvement coupled with favorable modulation of pyruvate and tryptophan supports advancing TTI-0102 to larger Phase 2b/3 trials in mitochondrial disease employing weight-based dosing (60 {+/-} 5 mg/kg), validated patient-reported outcomes, and minimum 12-week treatment duration. The same mechanism of cysteamine/cystine thiol-disulfide exchange in lysosomes that may benefit mitochondrial diseases also supports cystinosis treatment. An investigator-initiated study in cystinosis will evaluate whether once-daily TTI-0102 at 60 {+/-} 5 mg/kg can maintain therapeutic WBC cystine levels, potentially offering improved adherence and quality of life compared to current twice-daily or four-times-daily regimens, and this weight-adjusted dosing strategy and pharmacodynamic biomarkers identified in the MELAS study are going to be used to inform the design of the planned Phase 2 study in Leigh syndrome, another mitochondrial disorder, in collaboration with the Childrens Hospital of Philadelphia (CHOP), with particular attention to dose optimization and biomarker-based assessment of pharmacological activity.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.